EntryPoint Capital LLC purchased a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 26,731 shares of the company’s stock, valued at approximately $262,000.
A number of other large investors have also recently added to or reduced their stakes in DNA. Forbes J M & Co. LLP increased its position in shares of Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock worth $6,891,000 after purchasing an additional 576,732 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Ginkgo Bioworks in the third quarter valued at about $4,075,000. Jacobs Levy Equity Management Inc. acquired a new stake in Ginkgo Bioworks during the third quarter valued at approximately $2,282,000. BNP Paribas Financial Markets bought a new position in Ginkgo Bioworks during the 3rd quarter worth approximately $1,287,000. Finally, PDT Partners LLC acquired a new position in shares of Ginkgo Bioworks in the 3rd quarter worth approximately $1,199,000. 78.63% of the stock is currently owned by institutional investors.
Ginkgo Bioworks Trading Down 6.6 %
DNA stock opened at $6.16 on Friday. The stock’s 50 day simple moving average is $10.36 and its 200 day simple moving average is $9.22. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.26 and a 12-month high of $47.60. The firm has a market cap of $357.26 million, a P/E ratio of -0.47 and a beta of 1.23.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
- Five stocks we like better than Ginkgo Bioworks
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Overbought Stocks Explained: Should You Trade Them?
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- How to Plot Fibonacci Price Inflection Levels
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report).
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
